Literature DB >> 19277902

Frontiers proposal. National Institute on Aging "bench to bedside: estrogen as a case study".

Sanjay Asthana1, Roberta Diaz Brinton, Victor W Henderson, Bruce S McEwen, John H Morrison, Peter J Schmidt.   

Abstract

On 28-29 September 2004, the National Institute on Aging (NIA) convened scientists for a workshop on the aging female brain focused on translating into clinical practice discoveries concerning estrogens and progestogens. Workshop objectives were to examine effects of estrogen and progestogen on brain and cognitive function in relation to aging, to examine consistencies and apparent discrepancies between Women's Health Initiative Memory Study findings and other research on cognitive function, to determine whether additional hormone interventions could be developed in this area, and to offer advice on design of clinical trials for other interventions that might ameliorate cognitive aging. Following the workshop, participants joined by other interested scientists organized into regional work groups to continue the dialogue begun in Bethesda and to propose recommendations for NIA. The resulting recommendations, referred to as the "Frontiers Proposal for Estrogen and Cognitive Aging", acknowledge the persistence of critical gaps in our understanding of how decline in ovarian steroid secretion during reproductive aging and use of ovarian steroid hormone therapy affect normal brain function and risk for late-life neurodegenerative disorders such as Alzheimer's disease. There is a pressing need for preclinical, human, and integrated studies on the relationship between the menopausal transition and midlife exposures to estrogens, progestogens and related compounds, and risks for age-associated cognitive disorders. Research is also needed on better predictors of adverse cognitive outcomes, valid biomarkers for risks associated with hormone therapy use, enhanced tools for monitoring brain function and disease progression, and novel forms of therapy for improving long-term cognitive outcomes.

Entities:  

Year:  2009        PMID: 19277902      PMCID: PMC2734241          DOI: 10.1007/s11357-009-9087-2

Source DB:  PubMed          Journal:  Age (Dordr)        ISSN: 0161-9152


  55 in total

1.  "MENOPAUSAL SYMPTOMS" IN WOMEN OF VARIOUS AGES.

Authors:  B L NEUGARTEN; R J KRAINES
Journal:  Psychosom Med       Date:  1965 May-Jun       Impact factor: 4.312

2.  Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life.

Authors:  Kristine Yaffe; Eric Vittinghoff; Kristine E Ensrud; Karen C Johnson; Susan Diem; Vladimir Hanes; Deborah Grady
Journal:  Arch Neurol       Date:  2006-07

3.  Selection to postmenopausal therapy by women's characteristics.

Authors:  E Hemminki; M Malin; P Topo
Journal:  J Clin Epidemiol       Date:  1993-03       Impact factor: 6.437

4.  Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats.

Authors:  R B Gibbs
Journal:  Neurobiol Aging       Date:  2000 Jan-Feb       Impact factor: 4.673

5.  Bioavailable estradiol and age at onset of Alzheimer's disease in postmenopausal women with Down syndrome.

Authors:  Nicole Schupf; Susan Winsten; Bindu Patel; Deborah Pang; Michel Ferin; Warren B Zigman; Wayne Silverman; Richard Mayeux
Journal:  Neurosci Lett       Date:  2006-08-22       Impact factor: 3.046

6.  Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones.

Authors:  D D Murphy; M Segal
Journal:  J Neurosci       Date:  1996-07-01       Impact factor: 6.167

7.  Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.

Authors:  Roberta Diaz Brinton
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

8.  Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.

Authors:  Garnet L Anderson; Howard L Judd; Andrew M Kaunitz; David H Barad; Shirley A A Beresford; Mary Pettinger; James Liu; S Gene McNeeley; Ana Maria Lopez
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

9.  Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling.

Authors:  Jon Nilsen; Roberta Diaz Brinton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

10.  Effects of combination estrogen plus progestin hormone treatment on cognition and affect.

Authors:  Susan M Resnick; Pauline M Maki; Stephen R Rapp; Mark A Espeland; Robert Brunner; Laura H Coker; Iris A Granek; Patricia Hogan; Judith K Ockene; Sally A Shumaker
Journal:  J Clin Endocrinol Metab       Date:  2006-03-07       Impact factor: 5.958

View more
  14 in total

1.  Differential responses of progesterone receptor membrane component-1 (Pgrmc1) and the classical progesterone receptor (Pgr) to 17β-estradiol and progesterone in hippocampal subregions that support synaptic remodeling and neurogenesis.

Authors:  Namrata Bali; Jason M Arimoto; Nahoko Iwata; Sharon W Lin; Liqin Zhao; Roberta D Brinton; Todd E Morgan; Caleb E Finch
Journal:  Endocrinology       Date:  2011-12-06       Impact factor: 4.736

2.  Ovarian hormone loss induces bioenergetic deficits and mitochondrial β-amyloid.

Authors:  Jia Yao; Ronald Irwin; Shuhua Chen; Ryan Hamilton; Enrique Cadenas; Roberta Diaz Brinton
Journal:  Neurobiol Aging       Date:  2011-04-22       Impact factor: 4.673

3.  Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.

Authors:  Rima Hajjo; Vincent Setola; Bryan L Roth; Alexander Tropsha
Journal:  J Med Chem       Date:  2012-06-11       Impact factor: 7.446

4.  A mechanism emerges for the critical period hypothesis for estrogen treatment.

Authors:  John H Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-19       Impact factor: 11.205

Review 5.  The ageing cortical synapse: hallmarks and implications for cognitive decline.

Authors:  John H Morrison; Mark G Baxter
Journal:  Nat Rev Neurosci       Date:  2012-03-07       Impact factor: 34.870

6.  Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.

Authors:  Victor W Henderson; Roberta Diaz Brinton
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

7.  Cognitive response to estradiol in postmenopausal women is modified by high cortisol.

Authors:  Laura D Baker; Sanjay Asthana; Brenna A Cholerton; Charles W Wilkinson; Stephen R Plymate; Pattie S Green; George R Merriam; Mark A Fishel; G Stennis Watson; Monique M Cherrier; Monica L Kletke; Pankaj D Mehta; Suzanne Craft
Journal:  Neurobiol Aging       Date:  2011-08-19       Impact factor: 4.673

8.  Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor β-selective phytoSERM treatments.

Authors:  Jia Yao; Liqin Zhao; Zisu Mao; Shuhua Chen; Karren Carmen Wong; Jimmy To; Roberta Diaz Brinton
Journal:  Brain Res       Date:  2013-02-18       Impact factor: 3.252

Review 9.  Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.

Authors:  Jia Yao; Roberta Diaz Brinton
Journal:  Adv Pharmacol       Date:  2012

Review 10.  Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause.

Authors:  Victor W Henderson
Journal:  J Steroid Biochem Mol Biol       Date:  2013-05-28       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.